Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
In a retrospective cohort study of Lynch syndrome patients, researchers found that cancer onset varied both by which gene was mutated and how it was altered.
NGeneBio is moving ahead with plans to have the test cleared for diagnostic use in Korea, while envisioning a 2019 submission to the US FDA.
The Korean molecular diagnostics startup is planning to launch the new offering in Europe, as well as China and other Southeast Asian countries.
The Stanford University and Fox Chase Cancer Center team found that some mutations dramatically increased cancer risk, while others had a more modest effect.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
The BRCA Mastr Plus Dx assay and Mastr Reporter software identifies mutations in the coding regions of the BRCA1 and BRCA2 genes
The company plans to submit a package to the FDA by the end of this year for use of the system in metastatic breast cancer patients, and then add other cancer types in the future.
The study will use OncoDNA's liquid biopsy tech to profile and identify treatment options for 100 patients in Lebanon, Jordan, Saudi Arabia, and the UAE.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.
In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.
Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.
A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.